07:00 , Jun 24, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Various B cell lymphoma 2 (BCL-2; BCL2) A study in mice suggests that the BCL-2 antagonist ABT-737 could be useful for treating autoimmune...
07:00 , Aug 4, 2008 |  BC Week In Review  |  Company News

DelSite, Medline Industries Inc. deal

DelSite will sell its Carrington wound care division to Medline for an undisclosed sum. Medline already markets Carrington’s wound and skin care products under a 2000 deal (see BioCentury, Nov. 13, 2000). DelSite said the...
07:00 , May 26, 2008 |  BC Week In Review  |  Company News

Carrington, National Institutes of Health deal

Carrington’s DelSite Biotechnologies Inc. subsidiary extended a license to evaluate NIH’s polysaccharide technology’s ability to create a typhoid vaccine with DelSite’s GelSite delivery polymer. Terms were not disclosed (see BioCentury, May 21, 2007). Carrington Laboratories...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Clinical News

GelVac avian H5N1 influenza vaccine: Phase I start

This year, Carrington’s DelSite Biotechnologies Inc. unit will begin a dose-escalation, U.S. Phase I trial in healthy volunteers. Carrington Laboratories Inc. (OTCBB:CARN), Irving, Texas   Product: GelVac avian H5N1 influenza vaccine   Business: Infectious  ...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Clinical News

Carrington preclinical data

In rabbit and rat models of bird flu, Carrington's avian H5N1 influenza vaccine was safe and nontoxic. A Phase I trial of non-egg-based formulation of the vaccine delivered using the GelVac nasal powder delivery system...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

Carrington, ImmuneRegen deal

IRBO and CARN's DelSite Biotechnologies Inc. subsidiary will use DelSite's GelSite polysaccharide polymer to develop a topical formulation of IRBO's Homspera to prevent pandemic flu. Homspera, an analog of the naturally occurring immunomodulator substance P,...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Company News

Carrington, ElSohly Laboratories Inc. deal

CARN's DelSite Biotechnologies Inc. subsidiary and ElSohly amended a 2007 deal to increase the number of compounds ElSohly can combine with DelSite's GelSite polymer drug delivery technology. ElSohly is developing compounds to treat cancer and...
07:00 , Aug 20, 2007 |  BC Week In Review  |  Clinical News

GelVac avian H5N1 influenza vaccine: Phase I start

In 1Q08, CARN hopes to begin a Phase I trial in about 75 patients. Carrington Laboratories Inc. (CARN), Irving, Texas   Product: GelVac avian H5N1 influenza vaccine   Business: Infectious   Molecular target: NA  ...
07:00 , Jul 30, 2007 |  BC Week In Review  |  Company News

Brookwood Pharmaceuticals Inc., Carrington deal

CARN's DelSite Biotechnologies Inc. subsidiary extended by two years a collaboration with Brookwood exploring potential uses for CARN's GelSite natural polymer drug delivery technology to stabilize or deliver proteins and peptides (see BioCentury, Feb. 28,...
07:00 , Jun 25, 2007 |  BC Week In Review  |  Company News

Carrington board of directors update

Carrington Laboratories Inc. (CARN), Irving, Texas   Business: Dermatology, Infectious, Drug delivery   Appointed: Alex McPherson, former president and CEO of Biomira Inc.  ...